C4X Discovery Holdings PLC
LSE:C4XD

Watchlist Manager
C4X Discovery Holdings PLC Logo
C4X Discovery Holdings PLC
LSE:C4XD
Watchlist
Price: 12 GBX 27.32% Market Closed
Market Cap: 30.3m GBX
Have any thoughts about
C4X Discovery Holdings PLC?
Write Note

C4X Discovery Holdings PLC
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

C4X Discovery Holdings PLC
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
C4X Discovery Holdings PLC
LSE:C4XD
Total Current Assets
ÂŁ24.7m
CAGR 3-Years
10%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Total Current Assets
ÂŁ447.2m
CAGR 3-Years
30%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Total Current Assets
ÂŁ23m
CAGR 3-Years
-12%
CAGR 5-Years
29%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Total Current Assets
ÂŁ3.2m
CAGR 3-Years
-21%
CAGR 5-Years
-19%
CAGR 10-Years
-8%
Ergomed PLC
LSE:ERGO
Total Current Assets
ÂŁ66.9m
CAGR 3-Years
9%
CAGR 5-Years
25%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Total Current Assets
ÂŁ57.8m
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
48%
No Stocks Found

C4X Discovery Holdings PLC
Glance View

Market Cap
30.3m GBX
Industry
Life Sciences Tools & Services

C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).

C4XD Intrinsic Value
43.44 GBX
Undervaluation 72%
Intrinsic Value
Price

See Also

What is C4X Discovery Holdings PLC's Total Current Assets?
Total Current Assets
24.7m GBP

Based on the financial report for Jan 31, 2024, C4X Discovery Holdings PLC's Total Current Assets amounts to 24.7m GBP.

What is C4X Discovery Holdings PLC's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
15%

Over the last year, the Total Current Assets growth was 78%. The average annual Total Current Assets growth rates for C4X Discovery Holdings PLC have been 10% over the past three years , 15% over the past five years .

Back to Top